Citius Pharmaceuticals, a developer of drugs for bloodstream infections, lymphoma, and hemorrhoids, is one step closer to spinning off its oncology business as a separate Nasdaq-listed company. On Monday, August 5, shares of Citius Pharma rose nearly 3% on the news, despite a broader market selloff. Details Citius Pharma, with…